OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in public health
2023;11 1210253.

Cervical HPV infection in Yueyang, China: a cross-sectional study of 125,604 women from 2019 to 2022.

Jinfeng Hou, Min Zeng, Chongmei Liu, Bochao Xie, Yu Li, Longyun Wu, Long Zhu, Manqiu Li, Zhihui Zhang, Xiaoyun Zhang, Yangqing Ge
Author Information
  1. Jinfeng Hou: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
  2. Min Zeng: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
  3. Chongmei Liu: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
  4. Bochao Xie: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
  5. Yu Li: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
  6. Longyun Wu: Department of Pathology, Yueyang Central Hospital, Yueyang, China.
  7. Long Zhu: Department of Pathology, Huarong County People's Hospital of Hunan Province, Yueyang, China.
  8. Manqiu Li: Department of Pathology, Pingjiang People's Hospital of Hunan Province, Yueyang, China.
  9. Zhihui Zhang: Department of Pathology, Linxiang People's Hospital of Hunan Province, Yueyang, China.
  10. Xiaoyun Zhang: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
  11. Yangqing Ge: Department of Gynecology, Yueyang People's Hospital, Hunan Normal University, Yueyang, China.
PMID: 37601194 DOI: 10.3389/fpubh.2023.1210253

Abstract

Objective: Human papillomavirus (HPV) infection is currently the main cause of cervical cancer and precancerous lesions in women. The aim of this study was to investigate the epidemiological characteristics of HPV genotypes among women in Yueyang city and to provide a basis for the prevention and treatment of cervical cancer in this city.
Methods: A cross-sectional study was conducted on 125,604 women who had received treatment from eight hospitals in Yueyang city from September 2019 to September 2022. Analysis of the prevalence of HPV in patients.
Results: The prevalence of HPV was 20.5% (95%CI: 20.2-20.7%), of which the high-risk type (HR-HPV) accounted for 17.5% (95%CI: 17.3-17.7%) and the low-risk type (LR-HPV) accounted for 5.0% (95%CI: 4.9-5.1%). Among the HR-HPV subtypes, the top five in prevalence, from the highest to the lowest, were HPV52 (5.1%), HPV16(2.7%), HPV58 (2.6%), HPV53 (2.4%), and HPV51 (1.7%). The main LR-HPV infection types were HPV81 (2,676 cases, OR = 2.1%; 95%CI, 2.0-2.1%). Among the infected patients, 19,203 cases (OR = 74.3%; 95%CI, 73.8-74.9%) had a single subtype, 4,673 cases (OR = 18.1%; 95%CI, 17.6-18.6%) had two subtypes, and 1957 cases (OR = 7.6%; 95%CI, 7.3-7.9%) had three or more subtypes. HPV prevalence is highest among women <25 years, 55-64 years and ≥ 65 years of age.
Conclusion: The prevalence of HPV in women in Yueyang city was 20.5%, with HR-HPV being dominant. As women aged <25 years, 55-64 years, and ≥ 65 years are at a relatively higher risk, more attention should be paid to them for prevention and control of HPV infections.

Keywords

cervical lesions epidemiology genotypes human papillomavirus prevalence

References

  1. Epidemiol Infect. 2017 Jan;145(2):245-253 [PMID: 27760573]
  2. Oncotarget. 2016 Apr 26;7(17):24656-63 [PMID: 27013587]
  3. Lancet Oncol. 2009 Apr;10(4):321-2 [PMID: 19350698]
  4. BMC Womens Health. 2019 Jul 8;19(1):90 [PMID: 31286939]
  5. Lancet. 2013 Sep 7;382(9895):889-99 [PMID: 23618600]
  6. Br J Cancer. 2021 Feb;124(4):777-785 [PMID: 33191407]
  7. J Med Virol. 2015 Nov;87(11):1966-72 [PMID: 26073652]
  8. J Infect Dis. 2010 Dec 15;202(12):1789-99 [PMID: 21067372]
  9. Am J Manag Care. 2006 Dec;12(17 Suppl):S462-72 [PMID: 17203990]
  10. Nature. 2012 Aug 30;488(7413):S2-3 [PMID: 22932437]
  11. PLoS One. 2015 Jul 24;10(7):e0133635 [PMID: 26207895]
  12. BMC Infect Dis. 2019 Jul 29;19(1):670 [PMID: 31357941]
  13. PLoS One. 2019 Jan 17;14(1):e0210311 [PMID: 30653566]
  14. BMC Infect Dis. 2017 Mar 23;17(1):226 [PMID: 28335818]
  15. Trans R Soc Trop Med Hyg. 2021 Jan 7;115(1):30-37 [PMID: 32838408]
  16. J Cancer. 2019 Apr 21;10(8):1902-1908 [PMID: 31205548]
  17. BMJ Open. 2017 Jun 9;7(6):e014135 [PMID: 28601819]
  18. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  19. J Med Virol. 2018 Jan;90(1):157-164 [PMID: 28700089]
  20. Hum Vaccin Immunother. 2020 Jul 2;16(7):1645-1652 [PMID: 31809222]
  21. J Med Virol. 2019 Oct;91(10):1856-1865 [PMID: 31206752]
  22. Lancet Oncol. 2010 Nov;11(11):1048-56 [PMID: 20952254]
  23. Front Oncol. 2021 Feb 17;10:606335 [PMID: 33680928]
  24. Int J Cancer. 2014 Dec 1;135(11):2604-11 [PMID: 24740547]
  25. BMC Infect Dis. 2020 Dec 4;20(1):926 [PMID: 33276740]
  26. Virol J. 2017 Apr 21;14(1):84 [PMID: 28431558]
  27. Virol J. 2010 Mar 23;7:66 [PMID: 20307327]
  28. J Low Genit Tract Dis. 2016 Oct;20(4):327-31 [PMID: 27482797]
  29. Virol J. 2020 Jun 26;17(1):84 [PMID: 32586352]
  30. Virol J. 2021 Oct 20;18(1):208 [PMID: 34670576]

MeSH Term

Papillomavirus Infections
China
Female
Uterine Cervical Neoplasms
Papillomaviridae
Cross-Sectional Studies
Alphapapillomavirus
Humans
Human Papillomavirus Viruses
Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Created with Highcharts 10.0.0HPVwomenprevalence1%2Yueyangcity7%cases95%CIinfectioncervicalstudy205%95%CI:HR-HPV17subtypes6%papillomavirusmaincancerlesionsgenotypesamongpreventiontreatmentcross-sectional125604September20192022patientstypeaccountedLR-HPV54Amonghighest9%<25 years55-64 yearsand ≥ 65 yearsObjective:HumancurrentlycauseprecancerousaiminvestigateepidemiologicalcharacteristicsprovidebasisMethods:conductedreceivedeighthospitalsAnalysisResults:2-20high-risk3-17low-risk0%9-5topfivelowestHPV52HPV16HPV58HPV534%HPV511typesHPV81676OR = 20-2infected19203OR = 743%738-74singlesubtype673OR = 186-18two1957OR = 773-7threeageConclusion:dominantagedrelativelyhigherriskattentionpaidcontrolinfectionsCervicalChina:epidemiologyhuman

Similar Articles

Cited By